Examining prevalence and correlates of smoking opioids in British Columbia: opioids are more often smoked than injected.
Inhaling
Mode of administration
Opioids
People who use drugs
Smoking
Journal
Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060
Informations de publication
Date de publication:
18 10 2021
18 10 2021
Historique:
accepted:
05
10
2021
entrez:
19
10
2021
pubmed:
20
10
2021
medline:
23
11
2021
Statut:
epublish
Résumé
British Columbia (BC) is in the midst of an opioid overdose crisis. Since 2017, smoking illicit drugs has been the leading mode of drug administration causing overdose death. Yet, little is known about people who smoke opioids, and factors underlying choice of mode of administration. The study objectives are to identify the prevalence and correlates associated with smoking opioids. The Harm Reduction Client Survey is a monitoring tool used by the BC Centre for Disease Control since 2012. This survey is disseminated to harm reduction sites across BC to understand drug use trends and drug-related harms. We examined data from the survey administered October-December 2019 and performed descriptive, univariate, and multivariate analyses to better understand factors associated with smoking opioids. A total of 369 people who used opioids in the past 3 days were included, of whom 251 (68.0%) reported smoking opioids. A total of 109 (29.5%) respondents experienced an overdose in the past 6 months; of these 79 (72.5%) smoked opioids. Factors significantly associated with smoking opioids were: living in a small community (AOR =2.41, CI =1.27-4.58), being a woman (AOR = 1.84, CI = 1.03-3.30), age under 30 (AOR = 5.41, CI = 2.19-13.40) or 30-39 (AOR = 2.77, CI = 1.33-5.78) compared to age ≥ 50, using drugs alone (AOR = 2.98, CI = 1.30-6.83), and owning a take-home naloxone kit (AOR = 2.01, CI = 1.08-3.72). Reported use of methamphetamines within the past 3 days was strongly associated with smoking opioids (AOR = 6.48, CI = 3.51-11.96). Our findings highlight important correlates associated with smoking opioids, particularly the recent use of methamphetamines. These findings identify actions to better respond to the overdose crisis, such as targeted harm reduction approaches, educating on safer smoking, advocating for consumption sites where people can smoke drugs, and providing a regulated supply of opioids that can be smoked.
Sections du résumé
BACKGROUND
British Columbia (BC) is in the midst of an opioid overdose crisis. Since 2017, smoking illicit drugs has been the leading mode of drug administration causing overdose death. Yet, little is known about people who smoke opioids, and factors underlying choice of mode of administration. The study objectives are to identify the prevalence and correlates associated with smoking opioids.
METHODS
The Harm Reduction Client Survey is a monitoring tool used by the BC Centre for Disease Control since 2012. This survey is disseminated to harm reduction sites across BC to understand drug use trends and drug-related harms. We examined data from the survey administered October-December 2019 and performed descriptive, univariate, and multivariate analyses to better understand factors associated with smoking opioids.
RESULTS
A total of 369 people who used opioids in the past 3 days were included, of whom 251 (68.0%) reported smoking opioids. A total of 109 (29.5%) respondents experienced an overdose in the past 6 months; of these 79 (72.5%) smoked opioids. Factors significantly associated with smoking opioids were: living in a small community (AOR =2.41, CI =1.27-4.58), being a woman (AOR = 1.84, CI = 1.03-3.30), age under 30 (AOR = 5.41, CI = 2.19-13.40) or 30-39 (AOR = 2.77, CI = 1.33-5.78) compared to age ≥ 50, using drugs alone (AOR = 2.98, CI = 1.30-6.83), and owning a take-home naloxone kit (AOR = 2.01, CI = 1.08-3.72). Reported use of methamphetamines within the past 3 days was strongly associated with smoking opioids (AOR = 6.48, CI = 3.51-11.96).
CONCLUSIONS
Our findings highlight important correlates associated with smoking opioids, particularly the recent use of methamphetamines. These findings identify actions to better respond to the overdose crisis, such as targeted harm reduction approaches, educating on safer smoking, advocating for consumption sites where people can smoke drugs, and providing a regulated supply of opioids that can be smoked.
Identifiants
pubmed: 34663374
doi: 10.1186/s13011-021-00414-6
pii: 10.1186/s13011-021-00414-6
pmc: PMC8522853
doi:
Substances chimiques
Analgesics, Opioid
0
Smoke
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
79Informations de copyright
© 2021. The Author(s).
Références
NIDA Res Monogr. 1997;167:17-36
pubmed: 9243555
PLoS One. 2021 May 26;16(5):e0252090
pubmed: 34038452
Int J Drug Policy. 2020 Mar;77:102665
pubmed: 31962283
Drug Alcohol Depend. 2017 Jun 1;175:140-145
pubmed: 28414990
Drug Alcohol Depend. 2019 Dec 1;205:107609
pubmed: 31654839
N Engl J Med. 2012 Jul 12;367(2):146-55
pubmed: 22784117
Drug Alcohol Depend. 2013 Dec 1;133(2):468-72
pubmed: 23910434
Drug Alcohol Depend. 2019 Dec 1;205:107579
pubmed: 31600619
Int J Drug Policy. 2020 Nov;85:102588
pubmed: 31753603
Health Place. 2012 Mar;18(2):152-62
pubmed: 21955638
Int J Drug Policy. 2020 Feb;76:102623
pubmed: 31865117
Drug Alcohol Depend. 2001 Jul 1;63(2):169-77
pubmed: 11376921
Harm Reduct J. 2017 May 18;14(1):28
pubmed: 28521829
Drug Alcohol Depend. 2018 Dec 1;193:69-74
pubmed: 30343236
Drug Alcohol Depend. 2018 Dec 1;193:14-20
pubmed: 30326396
Int J Drug Policy. 2021 May;91:103098
pubmed: 33476863
J Addict. 2013;2013:851840
pubmed: 24826370
Harm Reduct J. 2020 Nov 23;17(1):90
pubmed: 33228676
JAMA Neurol. 2018 Nov 1;75(11):1423-1434
pubmed: 29987325
Can J Public Health. 2019 Apr;110(2):210-215
pubmed: 30725386
Harm Reduct J. 2014 Apr 27;11:13
pubmed: 24766846
Drug Alcohol Depend. 2020 Mar 1;208:107878
pubmed: 32014646
Curr Opin Psychiatry. 2021 Jul 1;34(4):405-412
pubmed: 33901060
J Subst Abuse Treat. 2021 Jan;120:108158
pubmed: 33298298